Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of the Neurological Sciences|June 12, 2025
Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple sclerosisTamar Kvartskhava, David Freudenstein, Nicolas Sarmiento, et al.
Neurological Research and Practice|August 7, 2024
Real-world analysis of brain atrophy in multiple sclerosis patients with an artificial intelligence based software toolCaroline Reinhardt, Klemens Angstwurm, David Freudenstein, et al.
Therapeutic Advances in Neurological Disorders|November 4, 2024
The impact of different lifestyle factors on disability in multiple sclerosis at older ages: a monocentric retrospective studySophie Wecker, David Freudenstein, Iris Ganser, et al.
Frontiers in Neurology|December 22, 2025
Differential diagnoses of MS in clinical practice: incidence and methods for differential diagnosisTim Johannes Steinberg, Lucie Mayer, David Freudenstein, et al.
Scientific Reports|December 14, 2023
Endogenous Sox8 is a critical factor for timely remyelination and oligodendroglial cell repletion in the cuprizone modelDavid Freudenstein, Magdalena Lippert, Janina Sophie Popp, et al.
Frontiers in Immunology|August 26, 2024
Dietary galactose exacerbates autoimmune neuroinflammation via advanced glycation end product-mediated neurodegenerationStefanie Haase, Kristina Kuhbandner, Florian Mühleck, et al.
Frontiers in Immunology|June 30, 2026
Relative increase of memory B-cell subsets under s.c. B-cell-depleting therapies in multiple sclerosisAdriana Krenz, Anna-Lena Krickl, Felix Burner, et al.
Ebiomedicine|May 13, 2025
A probiotic approach identifies a Treg-centred immunoregulation via modulation of gut microbiota metabolites in people with multiple sclerosis and healthy individualsConstantin Träger, Maria Kaiser, David Freudenstein, et al.
Pageof 1